According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that:
- izokibep was less effective in treating Hidradenitis Suppurativa (“HS”) than defendants had led investors to believe;
- accordingly, ACELYRIN overstated izokibep’s clinical and/or commercial prospects;
- as a result, ACELYRIN also overstated ACELYRIN’s business prospects post-Initial Public Offering; and
- as a result, ACLEYRIN’s public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
